BG-75202 for Breast Cancer

This trial tests a new treatment called BG-75202 for individuals with advanced breast cancer and other solid tumors. Researchers aim to determine if BG-75202, alone or combined with other cancer-fighting drugs, is safe and effective in shrinking tumors. Participants should have advanced breast cancer, must have tried other treatments without success, and should be postmenopausal or receiving ovarian suppression. This trial offers an opportunity for those who have not yet received a CDK4/6 inhibitor and are seeking new options. As a Phase 1 trial, the research focuses on understanding how BG-75202 works in people, offering participants the chance to be among the first to receive this new treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research shows that BG-75202 is under study to assess its safety and tolerability. As this treatment remains in the early testing stages, detailed safety information is limited. Early trials primarily aim to determine human safety and establish the correct dosage.

While detailed information from past studies is scarce, the testing of BG-75202 indicates promise in earlier lab or animal research. This trial will evaluate human tolerance and potential side effects.

Researchers are excited about BG-75202 for breast cancer because it offers a novel approach compared to current treatments. Most treatments, like hormone therapies or chemotherapy, target cancer cells directly. However, BG-75202 is being tested in different combinations that uniquely target the pathways and receptors involved in cancer growth. For instance, when combined with a CDK4 inhibitor and an aromatase inhibitor, it aims to disrupt cancer cell division and hormone-driven growth more effectively. Additionally, in combinations with an estrogen receptor antagonist, it could block hormone signals that fuel cancer more comprehensively. This multi-faceted approach has the potential to enhance effectiveness and overcome resistance seen with existing therapies.

Research has shown that BG-75202, a new drug, may help treat breast cancer by targeting proteins that aid cancer growth. Early results suggest this drug can shrink tumors and slow their growth. In this trial, participants will receive BG-75202 in various combinations. Some will receive it with CDK4 and aromatase inhibitors, which studies indicate can enhance treatment effectiveness for certain breast cancer types. For patients with estrogen receptor-positive (ER+) breast cancer, other participants will receive BG-75202 combined with an estrogen receptor antagonist, potentially extending the time they live without cancer worsening. These combinations aim to provide better treatment options for advanced breast cancer.¹³⁵⁶⁷